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Abstract
Hepatocellular carcinoma is difficult to treat, primarily 
because the underlying molecular mechanisms driving 
clinical outcome are still poorly understood. Growing 
evidence suggests that the tissue microenvironment 
has a role in the biological behavior of the tumor. The 
main clinical issue is to identify the best target for 
therapeutic approaches. Here, we discuss the hypoth-
esis that the entire tissue microenvironment might be 
considered as a biological target. However, the tissue 
microenvironment consists of several cellular and bio-
chemical components, each of which displays a distinct 
biological activity. We discuss the major components of 
this environment and consider how they may interact 
to promote tumor/host crosstalk.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: We discuss a new hypothesis for therapeutic 
approaches in hepatocellular carcinoma (HCC). This 
novel idea is to regard the entire liver as responsible 
for the onset, growth and progression of HCC. In this 
scenario, we focus on the tissue microenvironment 
components as an ideal target for systemic therapies, 
taking into account the tumor/host interactions.
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INTRODUCTION
The tissue microenvironment consists of  a dynamic popu-
lation of  cellular and non-cellular components which form 
a multifaceted regulatory network that helps to maintain 
the homeostasis of  an organ. The liver microenvironment 
consists of  a heterogeneous multitude of  several compo-
nents including extracellular matrix (ECM) components 
(laminin, fibronectin, collagen and proteoglycans), im-
mune cells, Kupffer cells, endothelial cells, cytokines, 
fibroblasts and various growth factors[1]. These normal 
cellular and non-cellular microenvironment components 
are not only essential for the normal physiological and 
biological behavior of  an organ, but are critical in op-
posing resistance to malignant cell growth[2] (Figure 1A). 
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Fundamentally, a tumor and its microenvironment have 
a mutual influence on each other’s fate. Accumulations 
of  mutations in normal cells bring them to a benign 
tumor state, where they stay dormant because they lack 
the main hallmark of  cancer, namely the ability to in-
vade, metastasize and form vasculature (angiogenesis)[3,4]. 
These mutual interactions between the mutated cells 
and the microenvironment modulate the ECM compo-
sition; they activate fibroblasts, recruit immune or in-
flammatory cells and pericytes, and stimulate endothelial 
cells to invoke angiogenesis, stirring the cascade of  vari-
ous cytokines, chemokines and growth factors[5,6]. This 
interactive, complex communication between the tumor 
and its microenvironment components favors cancer 
progression.
During hepatocellular carcinoma (HCC) progression, 
as the microenvironment components continue to inter-
act with each other as well as with HCC cells, they ac-
quire an abnormal phenotype due to tissue remodeling, 
which contributes to modulate the biological behavior 
of  the tumor and thus facilitates cancer progression and 
metastasis.
The abrupt annual increase in HCC incidence in 
recent years of  more than 750000 cases worldwide has 
constantly driven efforts to find new potential therapies 
for HCC[7,8]. Although surgical resection and liver trans-
plantation are the so-called “curative treatments”, the 
limiting factors are a shortage of  healthy donor livers as 
compared to the emerging cases of  HCC, and the fact 
that in advanced stages of  HCC, surgery is not possible. 
Therefore, many studies have been focused on tumor-
destructive approaches. The neovascularized nature 
of  HCC is a potential target for the use of  systemic 
therapies that can impede aberrant molecular pathways. 
The use of  small molecule multi-kinase inhibitors such 
as Sorafenib has resulted in a significant improvement 
in overall survival of  patients with advanced HCC[9,10]. 
Sorafenib targets the vascular endothelial growth fac-
tor receptor (VEGFR), and various other multi-kinase 
inhibitors targeting VEGFR are undergoing clinical trial 
for the treatment of  HCC, such as sunitinib, axitinib, 
linifanib, pazopanib, vandetanib, cediranib and rego-
rafenib, as well as monoclonal antibodies such as beva-
cizumab[11]. Another approach, namely transarterial che-
moembolization (TACE), induces tumor hypoxia and 
this upregulates angiogenic factors such as VEGF[12,13]. 
TACE does not induce complete necrosis and after 
treatment the peripheral area of  the tumor becomes 
viable again due to re-vascularization[14]. Combination 
therapy has been tried, but several studies failed to ob-
serve any survival benefits after the use of  TACE with 
anti-angiogenic agents such as Sorafenib[15]. Cetuximab, 
a monoclonal antibody against the epidermal growth 
factor (EGFR), failed to show any significant activity 
against HCC in a phase Ⅱ study[16]. Clinical trials us-
ing small molecules targeting EGFR, such as erlotinib, 
gefitinib and lapatinib, were also ineffective against 
HCC[17-19]. A phase Ⅱ clinical trial of  a multi-targeted 
agent, namely Dovitinib, which targets VEGFR, plate-
let-derived growth factor receptor and fibroblast growth 
factor receptor, is now under way[20]. Apart from genetic 
defects, epigenetics also play a pivotal role in hepatocar-
cinogenesis. In vitro and in vivo data have shown that the 
use of  a histone deacetylase (HDAC) inhibitor (HDACi), 
along with dihydroartemisinin (DHA), elicited antitu-
mor activity in liver cancer[21]. Recently, a phase Ⅰ dose 
escalation trial of  an HDACi, CHR2845, against cancer-
associated inflammation in HCC was started in the 
United Kingdom. A pre-clinical Phase Ⅰ/Ⅱ study of  
the HDACi, PXD101 (belinostat), has also been con-
ducted and showed a good safety profile in HCC pa-
tients[22].
Due to the lack of  early stage HCC diagnostic mark-
ers and efficient chemo-preventive strategies to limit 
HCC progression once cirrhosis is established, the sur-
vival rate of  HCC patients is still poor and they mainly 
die of  tumor progression and metastasis. Tumor hetero-
geneity is also a crucial barrier to HCC treatment, as tu-
mor cells become resistant to chemotherapies[23]. In this 
scenario, it seems interesting to analyze the results of  
a potential therapeutic approach to HCC consisting of  
targeting the tumor tissue microenvironment. Tissue mi-
croenvironment components are genetically stable and 
are less likely to evolve into a drug-resistant phenotype, 
therefore it would be easier to target these components 
than tumor cells, which are genetically unstable and che-
motherapy-resistant[24]. Additionally, tumor stroma exerts 
tumor-suppressing as well as tumor-promoting signals. A 
pancreatic cancer mouse model showed that inhibition 
of  the Hedgehog signaling pathway reduced the level of  
tumor-associated stroma and improved the vascular de-
livery of  gemcitabine[25]. Nevertheless, although several 
theories have been proposed to explain the role of  stro-
ma in carcinogen-induced tumors, the actual relation-
ships are not yet proven. In addition, stromal cells may 
be a target for carcinogens, inducing either new cancers, 
or metastatic growth[26].
A better understanding of  the complex network of  
interactions between tumor cells and their milieu could 
offer new insight into novel targets for HCC treatment. 
In this review, we have updated the literature and dis-
cussed the various issues with the aim of  shedding fur-
ther light on the role of  the tissue microenvironment as 
a therapeutic target in HCC.
CELLULAR COMPONENTS OF THE 
TISSUE MICROENVIRONMENT
Cancer-associated fibroblasts
Cancer-associated fibroblasts (CAFs) are the major com-
ponent of  the tumor microenvironment and play a crucial 
role in tumor-stromal interactions[27-29]. CAFs promote tu-
mor progression, invasion and chemoresistance to clinical 
therapies[28,30,31]. The origin of  CAFs in HCC is contro-
versial and various studies have revealed multiple origins, 
including the trans-differentiation of  hepatic stellate cells 
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Figure 1  Progression of hepatocellular carcinoma: Crosstalk between hepatocellular carcinoma and its milieu. A: Healthy liver cell population. The normal 
liver cell population consists of quiescent hepatic stellate cell (HSC), Kupffer cells, and fenestrated endothelial cells which allow the exchange of blood and substrates 
between the space of Disse and hepatocytes; B: Fibrotic liver and its microenvironment. Fibrotic liver features cancer-injured hepatocytes, which trigger the release 
of transforming growth factor-β (TGF-β), defenestration of endothelial cells and recruitment of regulatory T-cells. Binding of TGF-β to its receptor on HSC triggers 
phosphorylation of SMAD2/3 signaling, which activates HSC to secrete extracellular matrix (ECM) components such as vimentin, CTGF, cytokeratin and muscle ac-
tin; C: Progression of liver cancer and its interaction with the milieu. Malignant hepatocytes proliferate in an uncontrolled manner. Infiltration of immune cells causes 
inflammation. Malignant hepatocytes secrete TGF-β which binds to, and activates, HSC. Activated HSC deposit more ECM. Recruitment of immune cells and cancer-
associated cells elicits a signaling cascade. Compressed air foam system (CAFs) secrete vascular endothelial growth factor (VEGF) to stimulate endothelial cells to 
induce angiogenesis. In turn, endothelial cells secrete VEGF and platelet-derived growth factor (PDGF), which triggers the release of hepatocyte growth factor (HGF) 
from HSC. HGF secreted by HSC promotes malignant hepatocyte proliferation. Also, PDGF induces the differentiation of HSC into myofibroblasts, which cause fibro-
sis and the development of HCC. Activated CAFs also secrete EGF, HGF, TGF-β and interleukin-6 (IL-6) to aid cancer cell proliferation. CAFs produce cyclo-oxygen-
ase-2 (COX-2) and IL-6 to induce tumor-associated macrophages (TAMs) production. Activated TAMs release TNF-α and PDGF to reinforce CAFs activation. Stromal 
cell-derived factor-1α (SDF-1/CXCL12) and its receptor CXCR4 are crucial in cancer stem cell (CSC) interactions with their surroundings. TGF-β upregulates CXCR4 
expression in liver cancer cells and allows them to migrate to SDF-1α enriched niches. D: Progression and growth of liver carcinoma. Angiogenesis, Invasion and Me-
tastasis are the crucial hallmarks of cancer. In HCC, HSC secrete VEGF to promote angiogenesis. CAFs and TAMs secrete various uPAs and matrix metalloproteinas-
es (MMPs) to induce metastasis. Cancer cells secrete E- selectin to induce metastasis. Cancer stem cells activate the Wnt, Notch, phosphoinositide 3-kinase/Protein 
Kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway and thus contribute to the molecular heterogeneity of liver cancer. CAFs secrete SDF/CXCL12 
to induce proliferation and invasion of liver tumor cells. Cytokines such as IL-6, IL-5, IL-22 and IL-17, produced by T regs or other immune cells, aid in liver cancer 
proliferation, angiogenesis and metastasis.
(HSC) during liver injury, activation of  resting fibrob-
lasts and a direct contribution of  hepatocytes through 
the epithelial to mesenchymal transition (EMT)[32]. CAFs 
modulate the biological activity of  HCC cells, as docu-
mented by the demonstration that lysophosphatidic acid 
induces HCC progression by recruiting peri-tumoral 
fibroblasts and promoting their trans-differentiation into 
myofibroblasts. In addition, activated CAFs create a fa-
vorable tumor environment by modulating immune cells 
such as NK cells. NK cells have anti-tumor activity, but 
this is significantly reduced in HCC[33]. Thus, activated 
CAFs remodel the ECM, which facilitates the release 
of  various cytokines and growth factors and as a result 
magnifies HCC growth. Transforming growth factor-β 
(TGF-β) activates CAFs, which display α-smooth muscle 
actin (α-SMA), fibroblast activation protein, fibroblast 
surface protein, and vimentin[27,29] expression. Because 
CAFs also enhance the metastatic potential of  HCC 
cells, targeting TGF-β receptor type Ⅰ using LY2109761 
can down-regulate CTGF production, which in turn in-
terferes with the crosstalk between CAFS and HCC cells, 
and hence inhibits stromal growth and metastasis[34] (Fig-
ure 1B). These findings clearly demonstrate that CAFs 
have an important role in overall cancer progression and 
hence are the significant modifiers of  cancer evolution. 
In certain types of  cancers, CAFs regulate cancer stem 
cells (CSCs), and since CSCs are resistant to chemo-
therapies it seems possible that this is one reason why 
HCC is difficult to treat, also due to its high recurrence 
rate, CAFs may regulate the stemness of  HCC. Further 
exploration of  the interactions between CAFs and HCC 
cells may help to identify novel HCC targets.
HSC
HSC, also known as lipocytes or Ito cells, are multifunc-
tional cells that perform several vital functions, including 
Vitamin A storage to maintain retinoid homeostasis[35], 
the production of  matrix metalloproteinases (MMPs) 
and ECM components such as collagen to remodel the 
ECM[36], the production of  various cytokines[37] (inter-
leukin-6 (IL-6), interleukin-1β (IL-1β), chemotactic pep-
tide-1, chemokines[38] (chemokine (C-C motif) ligands 
5 and 21 (CCL5), (CCL21) and growth factors (such as 
TGF-α, TGF-β), epidermal growth factor (EGF), plate-
let derived growth factor and basic fibroblast growth 
factor[39]. HSCs display different phenotypes according 
to their morphology, functions and gene expression. 
The normal healthy liver stores the quiescent phenotypic 
state of  HSCs, however, massive liver injury activates 
HSCs, leading to a cascade of  various cytokines, ECM 
components and the up-regulation of  cytoskeletal pro-
teins such as α-SMA[40]. Activated HSCs can proliferate 
through the action of  potent inducers such as cathep-
sins B and D, hepatitis virus B and C, PDGF, TGF-β1, 
MMP-9, JNK, insulin-like growth factor binding protein 
5, non-structural proteins that induce liver fibrosis and 
hepatocarcinogenesis, while adiponectin, for instance, 
suppresses HSC activation[41].
Apart from their active contribution in liver cirrhosis, 
these activated HSCs or myofibroblasts also infiltrate the 
stroma of  liver tumors, and when confined around the 
tumor sinusoids, fibrous septa and capsule, they assist in 
HCC progression[42] (Figure 1C). In vivo studies further 
support these data and showed that HSCs and HCC 
cells implanted into nude mice promote tumor growth 
and invasiveness by activating nuclear factor-κB and ex-
tracellular regulated kinase (ERK) in HCC cells[42]. HSCs 
produce and secrete laminin-5 (Ln-5), which induces 
HCC migration by activating the mitogen-activated pro-
tein kinase (MEK/MAPK)/extracellular-signal-regulated 
kinase (ERK) pathway, but not the phosphoinositide 
3-kinase (PI3K/Akt) pathway[43].
Being multifunctional in nature, HSCs also act as 
liver-specific pericytes and promote tumor vascularity[44]. 
Pericytes are characterized by the expression of  PGDF 
receptors; similarly, HSC cells produce PGDF and express 
PGDF receptors during liver injury[45,46]. Tumors and en-
dothelial cells secrete PGDF to stimulate and recruit peri-
cytes and so induce angiogenesis; pericytes secrete VEGF 
to support neovascularization[47]. These multifunctional 
phenotypes of  HSC display a pivotal role, suggesting that 
they may be a valid therapeutic target in HCC treatment.
Tumor-associated macrophages
Macrophages are circulatory immature monocytes re-
leased from bone marrow which travel through the 
blood circulation to reach their destined tissue, where 
they mature and undergo differentiation into resident 
macrophages, such as Kupffer cells in the liver. Tumor-
associated macrophages (TAMs) are the major inflam-
matory cells that infiltrate tumors. Tumor-derived 
signals such as macrophage-colony stimulating factor 
(M-CSF or CSF-1), VEGF, macrophage inflammatory 
protein 1a (MIP-1a), CCL3, CCL4, CCL5, CCL8, and 
angiopoietin-2, attract TAMs into the tumor micro-
environment[48]. Different microenvironment signals 
determine distinct polarized activation states of  mac-
rophages, namely the classically activated (M1) and the 
alternatively activated (M2) phenotypes. Lipopolysac-
charides (LPS) and Th-1 cytokine interferon-γ (IFN-γ) 
exposure polarizes macrophages to the M1 phenotype, 
whereas Th-2 cytokines interleukin-4 (IL-4), IL-10, and 
IL-13 exposure polarizes macrophages to the M2 phe-
notype[48,49]. The M1 phenotype displays high levels of  
antigen-presenting cells with an increased expression 
of  IL-12, whereas the M2 phenotype shows low levels 
of  antigen-presenting cells with a distinctive expression 
of  various cytokines such as IL-10 and TGF-β[50]. In 
the tumor microenvironment, TAMs are mostly polar-
ized towards the M2 phenotype, with a high expression 
of  IL-10, arginase I, IL-6 and low expression of  IL-12, 
tumor necrosis factor (TNF) and proinflammatory cy-
tokines such as nitric oxide (NO) and reactive oxygen 
species (ROS)[50-52]. An increased number of  TAMs is 
correlated with tumor cell proliferation, angiogenesis, 
metastasis and a poor prognosis[53]. Indeed, depletion 
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of  macrophages by sorafenib significantly inhibits tu-
mor progression, angiogenesis and metastasis[54]. Hence, 
TAMs are clearly essential for tumor growth. In human 
HCC, activated TAMs are localized within the peritu-
moral stroma and display strong expression of  human 
leukocyte antigen (HLA-DR), IL-6, IL-1β and IL-23, 
whereas within the cancer niche, TAMs exhibit low ex-
pression of  HLA-DR and IL-10[55]. Additionally, HCC 
cells recruit TAMs by secreting VEGF, TGF-β, PDGF, 
CCL2 and M-CSF and by expressing glypican-3[29,56,57]. 
TAMs secrete various cytokines, which contribute to 
the pathogenesis of  HCC. For instance, in a diethylni-
trosamine (DEN)-induced HCC mouse model system, 
DEN exposure promoted the release of  IL-6 from 
Kupffer cells in response to IL-1β from damaged hepa-
tocytes. Then, IL-6 promoted abnormal proliferation of  
the surviving hepatocytes by triggering the Signal Trans-
ducer and Activator of  Transcription 3 (STAT-3) and 
Extracellular-signal-Regulated Kinases (ERK) pathways, 
which in turn control target genes involved in both cell 
proliferation and survival, thus contributing to HCC 
progression[58]. Moreover, TAMs-derived cytokines and 
growth factors induce immune suppression and con-
tribute to tumor growth. IL-10 and TNF-α, secreted by 
TAMs in an autocrine manner, stimulate B7-H1 expres-
sion on macrophages and impair CD8+ T-cell activity, 
which allows immune escape of  tumor cells[59]. Since 
TAMs are the main infiltrating cells in the tumor micro-
environment, therefore, they may be a potential target 
for clinical therapy. A macrophage activation state with-
in peritumoral and tumoral tissue is a potent prognostic 
factor. TAMs secrete numerous cytokines, chemokines 
and growth factors, which support HCC progression 
as these TAMs-derived signals modulate the interaction 
with tumor cells. Moreover, TAMs support angiogen-
esis, metastasis, and cancer progression. Therefore, the 
complex network of  tumor-stroma crosstalk could be a 
promising target of  therapy for HCC.
Tumor-associated endothelial cells
The morphology of  tumor vasculature is different from 
that of  normal vessels. Tumor vessels are irregular, in-
complete and fenestrated blood vessels with an irregular 
blood flow and increased permeability; this is possibly 
due to the molecular and functional differences be-
tween tumoral and normal endothelial cells[60,61]. Tumor-
associated endothelial cells (TAECs) are cytogenetically 
abnormal[62] with a rapid turnover rate, enhanced mo-
bility, migration and high expression of  the endoglin 
marker (also known as CD 105 or TGF-β receptor)[57]. 
TAECs also contain several secretory organelles such as 
Weibel-Palade bodies, tissue plasminogen activator (tPA) 
organelles and type-2 chemokine containing organelles. 
These organelles secrete tPA, cytokines IL-8 and IL-6, 
monocyte chemoattractant protein-1 (MCP-1), and growth-
regulated oncogene-α (GRO-α)[57,63]. Insufficient radiof-
requency ablation (RFA) enhances TAEC migration and 
angiogenesis and promotes invasiveness of  the residual 
HCC[64] (Figure 1D).
NON-CELLULAR COMPONENTS IN THE 
TISSUE MICROENVIRONMENT
TGF-β structure and receptor
TGF-β is a cytokine and belongs to the TGF-β cytokines 
superfamily, which also includes activins, inhibins, Mulle-
rian inhibitor substance (Mis) and bone morpho-genetic 
proteins (BMPs). TGF-β is a multifunctional cytokine 
that can control proliferation, cellular differentiation, ad-
hesion, migration, apoptosis and other functions in most 
cells[65,66]. In mammals, TGF-β exists in three isoforms, 
TGF-β1, TGF-β2 and TGF-β3. TGF-β1 is the most 
abundant, showing the highest expression[65]. TGF-β 
can inhibit the proliferation of  most cell types, especially 
epithelial cells. Furthermore, it enhances the prolifera-
tion of  mesenchymal cells, producing the ECM, as well 
as inducing fibrosis[67]. There are two main receptors for 
TGF-β, namely TGF-β receptor Ⅰ or activin receptor-
like kinase (ALK), and TGF-β receptor Ⅱ. In mammals, 
7 types of  receptor Ⅰ and 5 types of  receptor Ⅱ have 
been found[68].
ECM
ECM contains various proteoglycans, glycoproteins, polysac-
charides and water[69]. Chemotaxis induces cell adhesion 
to the ECM, which is mediated by ECM receptors such 
as integrins, discoidin domain receptors and syndecans, 
as well as to various ECM components including fi-
bronectin, laminin, collagens and elastin[70]. Ln-5 is a cell 
adhesion glycoprotein belonging to the Laminin family 
which forms a mesh-like structure to resist the tensile 
forces in the basal lamina. Each laminin is a heterodimer 
and consists of  α3, β3 and γ2 chains encoded by three 
different genes, LAMA3, LAMB3 and LAMC2, respec-
tively[71]. Ln-5 with the γ2 chain is a marker of  invasive-
ness in several carcinomas, suggesting its role in tumor 
cell spread[72-74]. Ln-5 is not detected in normal liver, but 
shows high expression in HCC nodules, associated with 
a more proliferative and metastatic phenotype. The pres-
ence of  the Ln-5 γ2 chain in metastatic HCC is correlated 
with poor prognosis and survival[75,76]. In HCC, invasive 
tumor cells secrete TGF-β1, which triggers invasiveness 
and motility in Ln-5 by inducing the expression of  the 
transmembrane integrin receptor α3β1. Ln-5 also plays 
a crucial role in the epithelial to EMT, which is crucial in 
tumorigenesis. In HCC, Ln-5 upregulates the expression 
of  the transcriptional repressors Snail and Slug, which 
induce the EMT[77,78]. Ln-5, together with TGF-β1, pro-
motes the EMT in HCC by over-expressing Snail and 
Slug and downregulating E-cadherin, followed by translo-
cation of  β-catenin to the nucleus[78]. Gefitinib, a specific 
inhibitor of  EGFR, suppresses HCC growth by inhibit-
ing phosphorylation of  the receptor and subsequently the 
Akt and Erk1/2 pathways in HCC cells in vitro. However, 
the presence of  Ln-5 in HCC antagonises gefitinib’s ef-
ficacy in a dose-dependent manner, suggesting a potential 
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drug (gefitinib) failure in Ln-5 positive HCC cases[79].
CANCER STEM CELL NICHE AS 
A NEW PLAYER IN THE HCC 
MICROENVIRONMENT
Cancer stem cells in liver tumors
Constant proliferation of  stem cells occurs in renewing 
liver tissues, where mutations expand the altered stem 
cells, perpetuating and increasing the likelihood of  ad-
ditional mutations and tumor progression. Overall, many 
data indicate that liver stem/progenitor cells follow their 
own rules and regulations. The same signals that are es-
sential for their activation, expansion and differentiation 
are good candidates for the role of  contributing, under 
suitable conditions, to the paradigm of  transformation 
from a pro-regenerative to a pro-tumorigenic role[80] (Fig-
ure 2A, B). The fact that about 40% of  HCCs are clonal 
suggests that these tumors may originate from stem cell-
like precursors. Recent evidence supports the existence 
of  CSCs in HCC[81], which can be identified by several 
cell markers, including CD133, the epithelial cell-adhe-
sion molecule EpCAM, as well as CD90, CD44, CD13, 
OV6, ALDH enzymatic activity, and the side population 
of  cells (SP) revealed by Hoechst dye staining[82]. Indeed, 
the presence of  EpCAM+ cells has been associated 
with a poorly differentiated morphology and high serum 
alpha-fetoprotein levels in HCC, whereas the presence 
of  CD90+ cells was associated with a high incidence of  
distant organ metastasis[83]. Furthermore, circulating stem 
cell-like EpCAM+ tumor cells indicate a poor prognosis 
in HCC patients after curative resection. High CD44 
standard isoform (CD44s) expression is associated with 
the EMT profile and with intrahepatic dissemination of  
HCC after local ablation therapy[84]. The expression of  
CD133 confers a malignant potential by regulating metal-
loproteinases in HCC cells. Importantly, CD13 is a mark-
er for semiquiescent CSCs in human liver tumor cell lines 
and clinical samples. CD13+ cells predominate in the G0 
phase of  the cell cycle and typically form cellular clusters 
in cancer foci. Following treatment, these cells survived 
and were particularly abundant along the fibrous capsule 
where liver cancers usually relapse[85]. From the mecha-
nistic standpoint, CD13 reduced reactive oxygen species 
(ROS)-induced DNA damage after genotoxic chemo/ra-
diation stress and protected cells from apoptosis. In any 
case, these cells are likely resistant to targeted therapies 
such as sorafenib[86].
MECHANISM OF THE TGF-α SIGNALING 
PATHWAY
The TGF-β superfamily plays a key role in a wide range 
of  cellular processes and is therefore tightly regulated. 
The pathway is both positively and negatively modu-
lated, for example, by extracellular antagonists, ligand-
binding antagonists, and the regulation of  receptor 
function and inhibition by I-SMADs. Positive regula-
tion plays a key role in amplifying signaling through the 
TGF-β superfamily[87]. Negative regulation could be 
critical for the restriction and termination of  signaling. 
In order to prevent the type Ⅰ receptor from becoming 
activated, BAMBI binds to it and serves as a negative 
regulator of  the TGF-β signaling pathway. Similarly, 
FKBP12 can prevent phosphorylation by binding to 
the GS domain of  type Ⅰ receptors. The most im-
portant negative regulation in the signaling pathway 
is inhibition by I-SMAD, which plays a critical role in 
transduction of  the TGF-β signaling pathway. I-SMAD 
has different ways of  regulating signaling both in the 
cytoplasm and nucleus. SMAD7 has been proved to 
form a complex with the type Ⅰ receptor to inhibit 
R-SMADs binding to the receptor and prevent their 
phosphorylation[88]. In the nucleus, SMAD6 binds to 
the transcription factor Hoxc-8 and acts as an antago-
nist of  transduction. SMAD6 can also bind to DNA 
directly and recruit HDAC to inhibit transduction[89].
Non-SMAD signaling pathway
Besides the SMAD pathway, TGF-β also activates other 
signaling cascades. For example, TGF-β can activate 
TGF-β-kinase 1 (TAK 1), (ErK), p38, mitogen-activated 
protein kinase (MAPK) and Akt[90]. These non-canonical 
or non-SMAD dependent means of  activating the TGF-β 
pathway appear to involve signaling via jun N-terminal ki-
nase (JNK), p38 MAPK, ERK or MEKK. The TGF-β in-
hibitor, LY2109761, a surrogate compound of  LY2157299, 
has also shown inhibitory activity towards the non-canon-
ical pathway that includes FAK, β1 integrin, MEK, Erk, 
Akt, mTOR and PTEN, but not p-38-MAK-kinase[91]. In 
rat intestine or mink lung epithelial cells, rapid activation 
of  p21 (Ras) occurred after TGF-β treatment, which 
indicated that TGF-β could activate the Erk-MAPK 
signaling pathway[92,93]. In this case, TGF-β induced 
Erk activation and tyrosine phosphorylation. Similarly, 
TGF-β can rapidly activate JNK through MKK4 and p38 
MAPK through MKK3/6 in several cell lines[94]. In hu-
man prostate cancer cells, SMAD7 triggers apoptosis by 
an association with TAK1, MKK3 and p38 MAPK, to 
help activate the TAK1-p38 MAPK signaling pathway[90]. 
It is known that TGF-β is involved in activation of  the 
phosphoinositide 3-kinase (PI3K)-Akt signaling pathway, 
and recent studies also indicate that TGF-β utilizes the 
mTOR pathway to regulate cell survival, metabolism, 
migration, and invasion[95,96]. Moreover, TGF-β induced 
the activation or inactivation of  small GTPases and the 
phosphorylation of  Par6, which may be critical events 
leading to the EMT[97]. Both the SMAD and non-SMAD 
signaling pathways determine the end results of  the cel-
lular response to TGF-β.
ROLE OF TGF-α IN THE HCC 
MICROENVIRONMENT
In human HCC, cells with stem cell markers show a 
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Figure 2  Role of the stem cell niche in liver tumors. A: A hepatic lobule consists of one central vein and six surrounding portal triads, each of which has bile ducts, 
a hepatic artery and portal vein. BrdU-retaining cells (with black nuclei) represent putative stem cells (NSC) and are located in cholangiocytes of the intralobular bile 
duct, together with less-characterized null cells, small hepatocytes at the interface of cholangiocytes, and hepatocytes in the canals of Hering; B: A series of genetic 
and epigenetic changes in NSC (or committed progenitor cells) leads to the generation of cancer stem cell (CSC) and then to expansion of cells within the stem cell 
niche. The niche adapts to the presence of CSCs by recruiting cells that would not normally be present; C: The signaling pathways for the activation, expansion and 
differentiation of stem/progenitor cells are good candidates for contributing, under suitable conditions, to a pro-tumorigenic role. Migration and metastasis of CSCs is a 
multistep process, in which SDF-1 plays a crucial role by chemoattracting CXCR4+ tumor cells; D: Transforming growth factor-β (TGF-β)-induced transdifferentiation 
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EMT plays a fundamental role in tumor progression and metastasis and the TGF-β-induced EMT can guide cancer cells to delaminate from primary tumors, migrate 
along the extracellular matrix network, and arrive at the site of metastasis via the peripheral blood. HSC: Hepatic stellate cell; TAM: Tumor-associated macrophage; 
CAFs: Compressed air foam system; EGF: Endothelial growth factor; HGF: Hepatocyte growth factor; IL: Interleukin.
loss of  TGF-β receptor Ⅱ and ELF (a β-spectrin that 
propagates TGF-β signal), and a marked activation of  
the IL-6 pathway, which is the major stem cell signal-
ing pathway[98,99]. These data support the concept that 
the absence of  TGF-β-driven epithelial differentiation 
favours carcinogenesis. Indeed, in addition to the well-
known transcriptional responses predominantly address-
ing tumor suppressor actions, TGF-β induces other 
Smad-dependent or independent effects that contribute 
to tumor progression[100] (Figure 2C).
TGF-β induces trans-differentiation of  hepatocytes 
and liver tumor cells from an epithelial to a mesenchymal 
phenotype, which results in a population of  cells with 
putative liver progenitor properties[101,102]. Additionally, 
the TGF-β-induced EMT not only endows cells with 
migratory and invasive properties, but can also induce 
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cancer cells to dedifferentiate and gain cancer stem-cell-
like properties[103]. Snail1 Snail2 and Twist may actively 
participate in this process[100,102,104] (Figure 2D). Further-
more, other studies have demonstrated the capacity of  
TGF-β to induce/maintain a stemness phenotype in 
other tumors[105].
CONCLUSION
In conclusion, several components of  the tissue micro-
environment have been shown to participate in modulat-
ing the biological behavior of  HCC. Biological redun-
dancy complicates the understanding of  the tumor/host 
crosstalk. Nevertheless, we hypothesize that HCC should 
be considered as a tumor of  the whole liver, rather than 
just of  few hepatocytes that grow in nodules. Taking 
into account this scenario, new therapeutic approaches 
targeting the TGF-β pathway seem promising. Directed 
against the microenvironment, they might have the ef-
fect of  making this microenvironment more hostile to 
HCC progression. Up to now, targeting TGF-β in HCC 
has been considered a questionable approach in view of  
the tumor suppressor role that TGF-β exerts on cells. 
This apparent controversy has been addressed by exam-
ining the differences between the early and late TGF-β 
signature in patients with HCC[106]. The clinical role of  
the late signature has been further confirmed in a wider 
HCC molecular classification, suggesting a potential role 
for TGF-β as a possible therapeutic target[107]. Currently, 
a multicenter clinical trial is ongoing, evaluating the ef-
ficacy and effectiveness of  a TGF-β receptor Ⅰ kinase 
inhibitor (LY2157299) in patients with HCC. However, 
it is not yet possible to predict at which stage of  the 
disease such a drug would display the best therapeutic 
effect, as all the clinical trials so far have been restricted 
to patients with a more advanced disease stage of  HCC, 
for ethical reasons. Nor is it yet possible to predict which 
patients might benefit from such treatment, according to 
the etiology, and how the underlying liver disease might 
interfere in the tumor/stroma crosstalk.
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